Indiana University-Purdue University Indianapolis (IUPUI) / The PRL family of enzymes constitutes a unique class of protein tyrosine phosphatase, consisting of three highly homologous members (PRL-1, PRL-2, and PRL-3). Family member PRL-3 is highly expressed in a number of tumor types and has recently gained much interest as a potential prognostic indicator of increased disease aggressiveness and poor clinical outcome for multiple human cancers. PRL-1 and PRL-2 are also known to promote a malignant phenotype in vitro, however, prior to the present study, little was known about their expression in human normal or tumor tissues. In addition, the biological function of all three PRL enzymes remains elusive and the underlying mechanisms by which they exert their effects are poorly understood. The current project was undertaken to expand our knowledge surrounding the normal cellular function of the PRL enzymes, the signaling pathways in which they operate, and the roles they play in the progression of human disease. We first characterized the tissue distribution and cell-type specific localization of PRL-1 and PRL-2 transcripts in a variety of normal and diseased human tissues using in situ hybridization. In normal, adult human tissues we found that PRL-1 and PRL-2 messages were almost ubiquitously expressed. Only highly specialized cell types, such as fibrocartilage cells, the taste buds of the tongue, and select neural cells displayed little to no expression of either transcript. In almost every other tissue and cell type examined, PRL-2 was expressed strongly while PRL-1 expression levels were variable. Each transcript was widely expressed in both proliferating and quiescent cells indicating that different tissues or cell types may display a unique physiological response to these genes. In support of this idea, we found alterations of PRL-1 and PRL-2 transcript levels in tumor samples to be highly tissue-type specific. PRL-1 expression was significantly increased in 100% of hepatocellular and gastric carcinomas, but significantly decreased in 100% of ovarian, 80% of breast, and 75% of lung tumors as compared to matched normal tissues from the same subjects. Likewise, PRL-2 expression was significantly higher in 100% of hepatocellular carcinomas, yet significantly lower in 54% of kidney carcinomas compared to matched normal specimens. PRL-1 expression was found to be associated with tumor grade in the prostate, ovary, and uterus, with patient gender in the bladder, and with patient age in the brain and skeletal muscle. These results suggest an important, but pleiotropic role for PRL-1 and PRL-2 in both normal tissue function and in the neoplastic process. These molecules may have a tumor promoting effect in some tissue types, but inhibit tumor formation or growth in others. To further elucidate the signaling pathways in which the PRLs operate, we focused on PRL-1 and used microarray and microRNA gene expression profiling to examine the global molecular changes that occur in response to stable PRL-1 overexpression in HEK293 cells. This analysis led to identification of several molecules not previously associated with PRL signaling, but whose expression was significantly altered by exogenous PRL-1 expression. In particular, Filamin A, RhoGDIalpha, and SPARC are attractive targets for novel mediators of PRL-1 function. We also found that PRL-1 has the capacity to indirectly influence the expression of target genes through regulation of microRNA levels and we provide evidence supporting previous observations suggesting that PRL-1 promotes cell proliferation, survival, migration, invasion, and metastasis by influencing multi-functional molecules, such as the Rho GTPases, that have essential roles in regulation of the cell cycle, cytoskeletal reorganization, and transcription factor function. The combined results of these studies have expanded our current understanding of the expression and function of the PRL family of enzymes as well as of the role these important signaling molecules play in the progression of human disease.

Indiana University-Purdue University Indianapolis (IUPUI) / Phosphatase of Regenerating Liver 3 (PRL3) is suspected to be a causative factor toward cellular metastasis when overexpressed. To date, the molecular basis for PRL3 function remains an enigma, justifying the use of 'shot-gun'-style phosphoproteomic strategies to define the PRL3-mediated signaling network. On the basis of aberrant Src tyrosine kinase activation following ectopic PRL3 expression, phosphoproteomic data reveal a signal transduction network downstream of a mitogenic and chemotactic PDGF (α and β), Eph (A2, B3, B4), and Integrin (β1 and β5) receptor array known to be utilized by migratory mesenchymal cells during development and acute wound healing in the adult animal. Tyrosine phosphorylation is present on a multitude of signaling effectors responsible for Rho-family GTPase, PI3K-Akt, Jak-STAT3, and Ras-ERK1/2 pathway activation, linking observations made by the field as a whole under Src as a primary signal transducer. Our phosphoproteomic data paint the most comprehensive picture to date of how PRL3 drives pro-metastatic molecular events through Src activation. The Src-homology 2 (SH2) domain-containing tyrosine phosphatase 2 (SHP2), encoded by the Ptpn11 gene, is a bona-fide proto-oncogene responsible for the activation of the Ras/ERK1/2 pathway following mitogen stimulation. The molecular basis for SHP2 function is pTyr-ligand-mediated alleviation of intramolecular autoinhibition by the N-terminal SH2 domain (N-SH2 domain) upon the PTP catalytic domain. Pathogenic mutations that reside within the interface region between the N-SH2 and PTP domains are postulated to weaken the autoinhibitory interaction leading to SHP2 catalytic activation in the open conformation. Conversely, a subset of mutations resides within the catalytic active site and cause catalytic impairment. These catalytically impaired SHP2 mutants potentiate the pathogenesis of LEOPARD-syndrome (LS), a neuro-cardio-facial-cutaneous (NCFC) syndrome with very similar clinical presentation to related Noonan syndrome (NS), which is known to be caused by gain-of-function (GOF) SHP2 mutants. Here we apply hydrogen-deuterium exchange mass spectrometry (H/DX-MS) to provide direct evidence that LS-associated SHP2 mutations which cause catalytic impairment also weaken the autoinhibitory interaction that the N-SH2 domain makes with the PTP domain. Our H/DX-MS study shows that LS-SHP2 mutants possess a biophysical property that is absolutely required for GOF-effects to be realized, in-vivo.

Indiana University-Purdue University Indianapolis (IUPUI) / Juvenile Myelomonocytic Leukemia (JMML) is rare, fatal myeloproliferative disease (MPD) affecting young children, and is characterized by expansion of monocyte lineage cells and hypersensitivity to Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) stimulation. JMML is frequently associated with gain-of-function mutations in the PTPN11 gene, which encodes the protein tyrosine phosphatase, Shp2. Activating Shp2 mutations are known to promote hyperactivation of the Ras-Erk signaling pathway, but Akt is also observed to have enhanced phosphorylation, suggesting a potential role for Phosphatidylinositol-3-Kinase (PI3K)-Akt signaling in mutant Shp2-induced GM-CSF hypersensitivity and leukemogenesis. Having demonstrated that Class IA PI3K is hyperactivated in the presence of mutant Shp2 and contributes to GM-CSF hypersensitivity, I hypothesized the hematopoietic-specific Class IA PI3K catalytic subunit p110δ is a crucial mediator of mutant Shp2-induced PI3K hyperactivation and GM-CSF hypersensitivity in vitro and MPD development in vivo. I crossed gain-of-function mutant Shp2 D61Y inducible knockin mice, which develop fatal MPD, with mice expressing kinase-dead mutant p110δ D910A to evaluate p110δ’s role in mutant Shp2-induced GM-CSF hypersensitivity in vitro and MPD development in vivo. As a comparison, I also crossed Shp2 D61Y inducible knockin mice with mice bearing inducible knockout of the ubiquitously expressed Class IA PI3K catalytic subunit, p110α. I found that genetic interruption of p110δ, but not p110α, significantly reduced GM-CSF-stimulated hyperactivation of both the Ras-Erk and PI3K-Akt signaling pathways, and as a consequence, resulted in reduced GM-CSF-stimulated hyper-proliferation in vitro. Furthermore, I found that mice bearing genetic disruption of p110δ, but not p110α, in the presence of gain-of-function mutant Shp2 D61Y, had on average, smaller spleen sizes, suggesting that loss of p110δ activity reduced MPD severity in vivo. I also investigated the effects of three PI3K inhibitors with high specificity for p110δ, IC87114, GDC-0941, and GS-9820 (formerly known as CAL-120), on mutant Shp2-induced GM-CSF hypersensitivity. These inhibitors with high specificity for p110δ significantly reduced GM-CSF-stimulated hyperactivation of PI3K-Akt and Ras-Erk signaling and reduced GM-CSF-stimulated hyperproliferation in cells expressing gain-of-function Shp2 mutants. Collectively, these findings show that p110δ-dependent PI3K hyperactivation contributes to mutant Shp2-induced GM-CSF hypersensitivity and MPD development, and that p110δ represents a potential novel therapeutic target for JMML.

Indiana University-Purdue University Indianapolis (IUPUI) / Human traumatic spinal cord injuries (SCI) are primarily incomplete contusion or compression injuries at the cervical spinal level, causing immediate local tissue damage and a range of potential functional deficits. Secondary damage exacerbates initial mechanical trauma and contributes to function loss through delayed cell death mechanisms such as apoptosis and autophagy. As such, understanding the dynamics of cervical SCI and related intracellular signaling and death mechanisms is essential. Through behavior, Western blot, and histological analyses, alterations in phosphatase and tensin homolog (PTEN)/phosphatidylinositol-3-kinase (PI3K) signaling and the neuroprotective, functional, and mechanistic effects of administering the protein tyrosine phosphatase (PTP) inhibitor, potassium bisperoxo (picolinato) vanadium ([bpV[pic]) were analyzed following cervical spinal cord injury in rats. Furthermore, these studies investigated the combination of subacute Schwann cell transplantation with acute bpV(pic) treatment to identify any potential additive or synergistic benefits. Although spinal SC transplantation is well-studied, its use in combination with other therapies is necessary to complement its known protective and growth promoting characteristics. v The results showed 400 μg/kg/day bpV(pic) promoted significant tissue sparing, lesion reduction, and recovery of forelimb function post-SCI. To further clarify the mechanism of action of bpV(pic) on spinal neurons, we treated injured spinal neurons in vitro with 100 nM bpV(pic) and confirmed its neurprotection and action through inhibition of PTEN and promotion of PI3K/Akt/mammalian target of rapamycin (mTOR) signaling. Following bpV(pic) treatment and green fluorescent protein (GFP)-SC transplantation, similar results in neuroprotective benefits were observed. GFP-SCs alone exhibited less robust effects in this regard, but promoted significant ingrowth of axons, as well as vasculature, over 10 weeks post-transplantation. All treatments showed similar effects in forelimb function recovery, although the bpV and combination treatments were the only to show statistical significance over non-treated injury. In the following chapters, the research presented contributes further understanding of cellular responses following cervical hemi-contusion SCI, and the beneficial effects of bpV(pic) and SC transplantation therapies alone and in combination. In conclusion, this work provides a thorough overview of pathology and cell- and signal-specific mechanisms of survival and repair in a clinically relevant rodent SCI model.

Indiana University-Purdue University Indianapolis (IUPUI) / Autonomic innervation of the heart begins in utero and continues during the neonatal phase of life. A balance between the sympathetic and parasympathetic arms of the autonomic nervous system is required to regulate heart rate as well as the force of each contraction. Our lab studies the development of sympathetic innervation of the early postnatal heart in a conditional knockout (cKO) of Src homology protein tyrosine phosphatase 2 (Shp2). Shp2 is a ubiquitously expressed non-receptor phosphatase involved in a variety of cellular functions including survival, proliferation, and differentiation. We targeted Shp2 in post-migratory neural crest (NC) lineages using our novel Periostin-Cre. This resulted in a fully penetrant mouse model of diminished cardiac sympathetic innervation and concomitant bradycardia that progressively worsen. Shp2 is thought to mediate its basic cellular functions through a plethora of signaling cascades including extracellular signal-regulated kinases (ERK) 1 and 2. We hypothesize that abrogation of downstream ERK1/2 signaling in NC lineages is primarily responsible for the failed sympathetic innervation phenotype observed in our mouse model. Shp2 cKOs are indistinguishable from control littermates at birth and exhibit no gross structural cardiac anomalies; however, in vivo electrocardiogram (ECG) characterization revealed sinus bradycardia that develops as the Shp2 cKO ages. Significantly, 100% of Shp2 cKOs die within 3 weeks after birth. Characterization of the expression pattern of the sympathetic nerve marker tyrosine hydroxylase (TH) revealed a loss of functional sympathetic ganglionic neurons and reduction of cardiac sympathetic axon density in Shp2 cKOs. Shp2 cKOs exhibit lineage-specific suppression of activated pERK1/2 signaling, but not of other downstream targets of Shp2 such as pAKT (phosphorylated-Protein kinase B). Interestingly, restoration of pERK signaling via lineage-specific expression of constitutively active MEK1 (Mitogen-activated protein kinase kinase1) rescued TH-positive cardiac innervation as well as heart rate. These data suggest that the diminished sympathetic cardiac innervation and the resulting ECG abnormalities are a result of decreased pERK signaling in post-migratory NC lineages.

Indiana University-Purdue University Indianapolis (IUPUI) / Gain-of-function mutations in the KIT receptor tyrosine kinase have been associated with highly malignant human neoplasms. In particular, an acquired somatic mutation at codon 816 in the second catalytic domain of KIT involving an aspartic acid to valine substitution is found in patients with systemic mastocytosis (SM) and acute myeloid leukemia (AML). The presence of this mutation in SM and AML is associated with poor prognosis and overall survival. This mutation changes the conformation of the KIT receptor resulting in altered substrate recognition and constitutive tyrosine autophosphorylation leading to constitutive ligand independent growth. As there are currently no efficacious therapeutic agents against this mutation, this study sought to define novel therapeutic targets that contribute to aberrant signaling downstream from KITD816V that promote transformation of primary hematopoietic stem/progenitor cells in diseases such as AML and SM. This study shows that oncogenic KITD814V (murine homolog) induced myeloproliferative neoplasms (MPN) occurs in the absence of ligand stimulation, and that intracellular tyrosines are important for KITD814V-induced MPN. Among the seven intracellular tyrosines examined, tyrosine 719 alone has a unique role in regulating KITD814V-induced proliferation and survival. Residue tyrosine 719 is vital for activation of the regulatory subunit of phosphatidylinositol 3-kinase (PI3K), p85α, downstream from KITD814V. Downstream effectors of the PI3K signaling pathway, in of leukemic cells bearing KITD814V with an allosteric inhibitor of Pak or its genetic inactivation results in growth repression due to enhanced apoptosis. To assess the role of Rac GEFs in KITD814V induced transformation, EHop-016, an inhibitor of Rac, was used to specifically target Vav1, and found to be a potent inhibitor of human and murine leukemic cell growth. In vivo, the inhibition of Vav or Rac or Pak delayed the onset of MPN and rescued the associated pathology in mice. These studies provide insight on mechanisms and potential novel therapeutic targets for hematological malignancies harboring an oncogenic KIT mutation.

Indiana University-Purdue University Indianapolis (IUPUI) / Phosphatases of regenerating liver, consisting of PRL-1, PRL-2 and PRL-3, belong to a novel protein tyrosine phosphatases subfamily, whose overexpression promotes cell proliferation, migration and invasion and contributes to tumorigenesis and metastasis. However, although great efforts have been made to uncover the biological function of PRLs, limited knowledge is available on the underlying mechanism of PRLs’ actions, therapeutic value by targeting PRLs, as well as the physiological function of PRLs in vivo. To answer these questions, we first screened a phage display library and identified p115 RhoGAP as a novel PRL-1 binding partner. Mechanistically, we demonstrated that PRL-1 activates RhoA and ERK1/2 by decreasing the association between active RhoA with GAP domain of p115 RhoGAP, and displacing MEKK1 from the SH3 domain of p115 RhoGAP, respectively, leading to enhanced cell proliferation and migration. Secondly, structure-based virtual screening was employed to discover small molecule inhibitors blocking PRL-1 trimer formation which has been suggested to play an important role for PRL-1 mediated oncogenesis. We identified Cmpd-43 as a novel PRL-1 trimer disruptor. Structural study demonstrated the binding mode of PRL-1 with the trimer disruptor. Most importantly, cellular data revealed that Cmpd-43 inhibited PRL-1 induced cell proliferation and migration in breast cancer cell line MDA-MB-231 and lung cancer cell line H1299. Finally, in order to investigate the physiological function of PRLs, we generated mouse knockout models for Prl-1, Prl-2 and Prl-3. Although mice deficient for Prl-1 and Prl-3 were normally developed, Prl-2-null mice displayed growth retardation, impaired male reproductive ability and insufficient hematopoiesis. To further investigate the in vivo function of Prl-1, we generated Prl-1-/-/Prl-2+/- and Prl-1+/-/Prl-2-/- mice. Similar to Prl-2 deficient male mice, Prl-1-/-/Prl-2+/- males also have impaired spermatogenesis and reproductivity. More strikingly, Prl-1+/-/Prl-2-/- mice are completely infertile, suggesting that, in addition to PRL-2, PRL-1 also plays an important role in maintaining normal testis function. In summary, these studies demonstrated for the first time that PRL-1 activates ERK1/2 and RhoA through the novel interaction with p115 RhoGAP, targeting PRL-1 trimer interface is a novel anti-cancer therapeutic treatment and both PRL-1 and PRL-2 contribute to spermatogenesis and male mice reproductivity.

ICA512/PTPRN is a receptor tyrosine-like phosphatase implicated in the biogenesis and turnover of the insulin secretory granules (SGs) in pancreatic islet beta cells. Previously we found biophysical evidence that its luminal RESP18 homology domain (RESP18HD) forms a biomolecular condensate and interacts with insulin in vitro at close-to-neutral pH, that is, in conditions resembling those present in the early secretory pathway. Here we provide further evidence for the relevance of these findings by showing that at pH 6.8 RESP18HD interacts also with proinsulin—the physiological insulin precursor found in the early secretory pathway and the major luminal cargo of β-cell nascent SGs. Our light scattering analyses indicate that RESP18HD and proinsulin, but also insulin, populate nanocondensates ranging in size from 15 to 300 nm and 10e2 to 10e6 molecules. Co-condensation of RESP18HD with proinsulin/insulin transforms the initial nanocondensates into microcondensates (size >1 μm). The intrinsic tendency of proinsulin to self-condensate implies that, in the ER, a chaperoning mechanism must arrest its spontaneous intermolecular condensation to allow for proper intramolecular folding. These data further suggest that proinsulin is an early driver of insulin SG biogenesis, in a process in which its co-condensation with RESP18HD participates in their phase separation from other secretory proteins in transit through the same compartments but destined to other routes. Through the cytosolic tail of ICA512, proinsulin co-condensation with RESP18HD may further orchestrate the recruitment of cytosolic factors involved in membrane budding and fission of transport vesicles and nascent SGs.

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal. / Protein-protein interactions are an integral component of signal transduction pathways. The interactions are mediated by modular domains which are present within the structure of the signalling molecule. These domains include PDZ, SH2, SH3, WW, PTB and LIM domains. hPTP1E is a protein-tyrosine phosphatase which contains within its primary structure a region with homology to Band 4.1 proteins, five PDZ domains and a catalytic domain. While the function of this PTPase remains unknown, the structure of hPTP1E suggest it may recruit several proteins into a multiprotein complex. In order to understand the role of hPTP1E, the protein interactions within its signalling cascade were examined. hPTP1E interacts with ZRP-1 and GEF-5.1 via its second PDZ domain and tuberin via its fourth PDZ domain in the yeast two-hybrid system. In order to characterize these proteins and their interactions, antibodies were generated against ZRP-1 and GEF-5.1. The antibodies which detected the antigen expressed in bacteria were purified by affinity chromatography. The antibodies raised against ZRP-1 and hPTP1E detected proteins of appropriate molecular weights in total cell extracts. HPTP1E is ubiquitously expressed whereas ZRP-1 is restricted to HeLa and MCF-7 cells among the cells tested. Unfortunately, antibodies against GEF-5.1 did not detect a protein of the predicted molecular weight in any of the cell extracts. Immunoprecipitation of hPTP1E fi-om cells overexpressing regions of ZRP-1 and tuberin with a hemaglutinin tag demonstrated the presence of an interaction between the phosphatase and tuberin in vivo. However, ZRP-1 and hPTP1E did not interact under these experimental conditions. Confirmation of the yeast two-hybrid results provides further support for a possible role of hPTP1E in the regulation of endocytosis. Additional molecules involved in the signalling pathways involving hPTP1E were identified by interaction trap. In one study, the proline rich amino terminus of ZRP-1 interacted with several clones encoding a segment of hCDC47 and NtZRP-p33, a clone containing an SH3 domain. The significance of these findings is unknown. HCDC47 is a minichromosome maintenance protein wich regulate DNA replication. Further, a clone called KIAA0769 containing the sequence of NtZRP-p33 depicts the typical structure for a scaffolding protein. Another yeast-two hybrid cDNA library screening using the CDC25 homology domain of GEF-5.1 did not detect an interaction with any GTPase but with 14-3-3E. 14-3-3 proteins are regulatory molecules which interact with various types of proteins by means of a phosphorylated serine residue. Mutational analysis demonstrated that the interaction is dependent on the second serine residue within the consensus sequence RSLSQG found in GEF-5.1. The primary structure of the open reading frame of GEF-5.1 was analyzed using profilescan. The software predicted the presence of several domains including a cNMP binding domain, a LTE domain, a PDZ domain, a rasassociated domain and a CDC25 homology domain. A family of guanidine nucleotide exchange factors may exist as clones KIAA0313 and T14G10 have the same structure. These results indicate a role for GEF-5.1 in Ras signalling pathways. Further, its activity may be regulated by the binding of cNMP molecules and 14-3-3E. The identification of ZRP-1 and GEF-5.1 interacting proteins as well as the analysis of the primary structure of GEF-5.1 have provided additional information about the function of hPTP1E. This cytoplasmic phosphatase may be involved in the regulation of processes such as transcription, DNA replication and. Further, an interaction between tuberin and hPTP1E suggests a role for this PTPase in the regulation of endocytosis. / La phosphorylation des protéines est une modification post-traductionelle fréquemment employée pour moduler la transmission des signaux intracellulaires. Il est nécessaire qu'un équilibre du niveau de phosphorylation soit maintenu pour le fonctionnement normal de la cellule sinon des maladies comme le cancer peuvent apparaître. Les enzymes responsables de la phosphorylation des protéines sont les protéines kinases tandis que les protéines phosphatases enlèvent les groupements phosphate. Les résidus phosphorylés dans les protéines sont certains résidus sérines, thréonines et/ou tyrosines. Les différentes enzymes sont classées en deux familles selon leur spécificité. Les protéine-tyrosine phosphatases (PTPase) sont elles-même regroupées dans deux familles selon leur localisation intracellulaire: les PTPases de type récepteur et les phosphatases cytoplasmiques. La structure des phosphatases de type récepteur inclus un domaine extracellulaire, un domaine transmembranaire et un (ou deux) domaine(s) catalytique(s). Les PTPases cytoplasmiques contiennent un domaine catalytique unique et généralement un/ ou des domaine(s) responsable(s) de leur localisation intracellulaire ou impliqué(s) dans des interactions protéine-protéine. Dans notre laboratoire, une phosphatase cytoplasmique dénommée liPTP1E par nous (et PTPL1, PTPBAS, FAP par d'autres) a été isolée. En plus de son domaine catalytique, cette protéine-tyrosine phosphatase contient 1 domaine de type "Band 4.1" qui est impliqué dans la localisation de la protéine à la membrane cellulaire via une interaction avec le cytoskelette, et 5 domaines PDZ. Ces domaines PDZ sont en général impliqués dans les interactions protéineprotéine. Plusieurs études récentes ont tenté de définir la fonction de hPTP1E. Sato et ses collègues ont isolé hPTP1E lors d'un criblage d'une librairie d'ADNc en utilisant le système des deux-hybrides dans la levure avec la partie cytoplasmique du récepteur Fas, comme appât. Ils ont aussi démontré que hPTP1E peut inhiber l'effet apoptotique de Fas. L'apoptose des cellules cibles qui est induit par les lymphocytes T cytotoxiques utiliserait le système Fas. De plus, Fas pourrait être associé à des maladies auto-immunes. En plus, hPTP1E pourrait jouer un rôle dans l'apparition de cellules resistantes aux effets de Fas tel que retrouvées dans les sarcomes de Kaposi chez les sidéens. Malgré des données convaincantes, il reste quand même des doutes quant à l'importance de hPTP1E dans ces maladies. Ainsi une étude publiée n'a pu démontrer une interaction entre les homologues de Fas et hPTP1E chez la souris. Depuis d'autres groupes étudiant les interactions de hPTP1E ont découvert plusieurs protéines qui interagissent avec celle-ci. La première, PARG, est membre de la famille des Rho-GAP, des protéines impliquées dans l'activation des GTPases de type Rho. L'interaction aurait lieu avec le 4ième domaine PDZ de hPTP1E. De plus, le domaine LEVI de RIL interagirait avec hPTP1E via ses 2ième et 4ième domaines PDZ. La fonction biologique de ces interactions n'a toutefois pas été déterminée à ce jour. Pour caractériser la fonction biologique de hPTP1E, nous avons utilisé le système des deux-hybrides de la levure pour identifier des protéines qui interagiraient avec les domaines PDZ de hPTP1E. J'ai ainsi identifié deux protéines nommés ZRP-1 et GEF-5.1, qui se lient à hPTP1E. ZRP-1 possède une structure semblable à celle de zyxin.Ces deux dernières protéines contiennent une région amino-terminale riche en résidus proline et 3 domaines de type LEM à l'extrémité carboxyl terminale. GEF-5.1, d'autre part démontre une homologie marquée aux GEFs de la famille CDC25 impliquées dans l'activation des GTPases de la famille Ras. Des anticorps ont été générés contre ZRP-1, GEF-5.1 et hPTP1E afin de fournir les outils nécessaires pour mieux caractériser ces différentes protéines. Ainsi, j'ai exprimé et purifié le troisième domaine LIM de ZRP-1 ainsi que le domaine PDZ de GEF-5.1, sous forme de protéines de fusion avec la glutathioneS-transferase (GST). Ces protéines ont servis d'antigène pour générer des anticorps chez le lapin. Des anticorps dirigés contre le deuxième domaine PDZ de hPTP1E étaient déja disponibles dans le laboratoire. Ces anticorps ont été purifiés sur une colonne d'affinité GST. Les anticorps anti-ZRP-1 et anti-hPTP1E détectent tous les deux des protéines du poids moléculaire attendu. HPTP1E est exprimé d'une facon ubiquitaire tandis que l'expression de ZRP-1 est plus restrainte parmi les cellules testées. Toutefois, les immunoglobulines dirigées contre GEF-5.1 ne détectent aucune protéine du poids moléculaire attendu dans un extrait cellulaire brut. Parallèlement, d'autres membres du laboratoire ont démontré une interaction entre la tuberine, le produit du gène TSC2, un oncogène impliqué dans la sclérose tubéreuse, et le quatrième domaine PDZ de hPTP1E. Afin de caractériser ces interactions in vivo, des immunoprécipitations de hPTP1E à partir de cellules dans lesquelles une région de ZRP-1 et/ou de la tuberine étaient surexprimé ont été conduites. Sous les conditions expérimentales utilisées, ZRP-1 n'a pas co-immunoprécipité avec hPTP1E. Cependant une interaction avec la tuberine a été détectée utilisant cette stratégie suggérant que HPTP1E pourrait jouer un rôle dans la modulation de l'endocytose. La structure de ZRP-1 inclus un domaine riche en proline qui n'est pas nécessaire pour son interaction avec hPTP1E mais qui pourrait interagir avec d'autres protéines en particulier avec des protéines contenant un/ ou des domaine(s) SH3. La moitié amino-terminale de ce domaine a été utilisé pour cribler une librairie d'ADNc par le système des deux-hybrides. Un clone appelé NtZRP-p33 contenant un domaine SH3 a été identifié. La conséquence biologique de cette interaction reste toutefois a être déterminée. Cependant, NtZRP-p33 possède une structure suggérant son implication dans la signalisation intracellulaire. Un deuxième criblage de la librairie d'ADNc a été initié pour caractériser les protéines impliquées dans le mécanisme de signalisation de hPTP1E. En utilisant le domaine de GEF-5.1 homologue à CDC25, des clones correspondants à la protéine 14-3-3 ont été isolés. Les protéines 14-3-3 forment une famille de protéines qui régularisent la fonction de plusieurs protéines. Leurs interactions se font via un residu sérine qui est phosphorylé. Des mutations du domaine catalytique ont démontré que l'interaction entre 14-3-3s et GEF-5.1 est dépendante du deuxième sérine de la séquence RSLSQG qui se retrouve immédiatement du coté carboxyl terminale du domaine GEF de la protéine GEF-5.1. Ces résultats suggèrent que l'activité de GEF-5.1 pourrait être modulée par la 14-3-38. En conclusion, les résultats expérimentaux présentés dans ce mémoire indique un rôle potentiel de hPTP1E dans plusieurs fonctions cellulaires. En s'associant à la tuberine, hPTP1E pourrait régulariser l'endocytose. Aussi, cette PTPase pourrait être impliquer dans le cycle cellulaire. Ras étant un activateur de la mitose, HPTP1E pourrait moduler l'activité de Ras par voie de GEF-5.1. Ainsi, hPTP1E pourrait agir comme proto-oncogène ou un gène suppresseur des tumeurs. Zyxin est une protéine qui se retrouve près des sites membranaires en association avec le cytoskelette. Puisque la structure de ZRP-1 et zyxin est semblable, ce dernier sert de modèle pour la fonction de ZRP-1. En collaboration avec hPTP1E, ces deux protéines pourrait régulariser la structure du cytoskelette.